Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Editorial urges ’black-box’ warning for Bextra and Celebrex

19.01.2005


Physicians should avoid prescribing Bextra altogether, or use it only as a drug of last resort, says a researcher from Wake Forest University Baptist Medical Center and colleagues in an editorial published on-line Jan. 17 in Circulation, a publication of the American Heart Association.



Curt D. Furberg, M.D., Ph.D., professor of public health sciences, and colleagues describe an analysis of two studies revealed that patients treated with Bextra after heart bypass surgery tripled their risk of heart attack and stroke compared to patients who received a placebo, or "dummy" drug. The data is a followup to information reported at the American Heart Association meeting in November.

"These data raise questions about the safety of the drug in other patients who have heart conditions, but who aren’t having surgery," said Furberg. "In the absence of evidence of safety, it is prudent to avoid the use of Bextra altogether or use it only as a drug of last resort," says the editorial. Furberg’s co-authors are Bruce M. Psaty, M.D., Ph.D., from the University of Washington in Seattle, and Garret A. FitzGerald, M.D., from the University of Pennsylvania.


The researchers say the Bextra results, combined with studies showing cardiovascular hazards with Celebrex and Vioxx, "provide compelling evidence that these adverse coronary and cerebrovascular events represent a class effect…" The drugs are all part of a class called COX-2 inhibitors. "A black-box warning that alerts practitioners to the potential cardiovascular hazards, especially in patients at moderate to high risk, seems timely for all COX-2 inhibitors," said Psaty.

Furberg supports the advice of the Food and Drug Administration, which issued a Public Health Advisory on COX-2 inhibitors and other non-steroidal anti-inflammatory drug products urging physicians to weigh the benefits against the risk for individual patients.

In the editorial, the authors support research to learn whether the drugs can be safely given for extended periods to patients at low risk of cardiovascular disease. "It is currently unclear to what degree the risk extends to patients treated with lower doses for arthritis because studies of sufficient size and duration have not been reported," Furberg said.

FitzGerald, who has been studying COX-2 inhibitors for more than six years, says that plans by Pfizer to study potential cardiovascular benefits of Celebrex are ill-advised.

In a separate article in Circulation, FitzGerald and colleagues report on evidence from mice showing that the combination of aspirin and a COX-2 inhibitor could make plaque in the arteries more likely to rupture and cause clotting, resulting in heart attack or stroke. "These results have disturbing implications for patients at high cardiovascular risk treated with aspirin and a COX inhibitor," writes FitzGerald.

Karen Richardson | EurekAlert!
Further information:
http://www.wfubmc.edu

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>